Skip to main content

Table 6 Lipid parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

  Increased LDL-C group (n = 20) Decreased LDL-C group (n = 20) p valuesb p valuesc
Pre treatment Post treatment % change p valuesa Pre treatment Post treatment % change p valuesa
Total-C (mg/dL) 188.9 ± 31.3 211.4 ± 43.1 11.9 <0.001* 198.4 ± 41.8 184.8 ± 45.8 −6.9 0.002* 0.428 <0.0001*
TG (mg/dL) 161.3 ± 69.5 151.6 ± 89.4 −6.0 0.440 123.0 ± 51.8 114.8 ± 54.6 −6.7 0.360 0.029* 0.920
HDL-C (mg/dL) 45.4 ± 8.5 52.0 ± 9.7 14.5 0.001* 51.5 ± 12.7 55.1 ± 16.0 7.0 0.070 0.082 0.242
LDL-C (mg/dL) 116.8 ± 23.0 133.4 ± 33.1 14.2 0.002* 119.8 ± 40.1 103.5 ± 41.0 −13.6 <0.001* 0.771 <0.0001*
Apo AI (mg/dL) 126.1 ± 17.8 140.4 ± 18.4 11.3 <0.001* 141.4 ± 22.9 146.8 ± 26.4 3.8 0.230 0.025* 0.145
Apo AII (mg/dL) 29.5 ± 4.8 32.3 ± 5.1 9.5 <0.001* 29.9 ± 4.3 29.5 ± 4.6 −1.3 0.530 0.798 0.001*
Apo B (mg/dL) 100.9 ± 17.6 111.8 ± 22.3 10.8 <0.001* 99.3 ± 30.0 85.0 ± 34.7 −14.4 0.014* 0.846 <0.0001*
Apo CII (mg/dL) 4.8 ± 1.8 5.4 ± 2.5 12.5 0.057 4.7 ± 1.6 4.5 ± 1.8 −4.3 0.270 0.855 0.029*
Apo CIII (mg/dL) 10.7 ± 3.6 12.0 ± 4.8 12.1 0.035* 10.2 ± 2.8 10.7 ± 3.8 4.9 0.340 0.698 0.240
Apo E (mg/dL) 4.3 ± 1.1 4.6 ± 1.7 7.0 0.280 4.4 ± 1.2 4.3 ± 1.3 −2.3 0.420 0.904 0.193
RLP-C (mg/dL) 7.6 ± 5.0 7.8 ± 2.5 2.6 0.870 5.7 ± 3.3 5.0 ± 3.3 −12.3 0.090 0.136 0.809
HDL2-C (mg/dL) 23.5 ± 5.1 29.1 ± 7.8 23.8 <0.001* 28.8 ± 10.03 32.5 ± 13.3 12.8 0.080 0.043* 0.437
HDL3-C (mg/dL) 21.8 ± 4.0 22.8 ± 4.9 4.6 0.410 22.6 ± 3.6 22.5 ± 5.2 −0.4 0.890 0.476 0.450
sd LDL-C (mg/dL) 62.0 ± 25.5 49.5 ± 24.5 −20.2 0.048* 46.3 ± 21.4 37.3 ± 23.2 −19.4 0.015* 0.046* 0.655
lb LDL-C (mg/dL) 54.7 ± 25.3 83.5 ± 32.3 52.7 <0.001* 73.4 ± 27.3 66.1 ± 34.4 −9.9 0.010* 0.033* <0.0001*
sd LDL-C/LDL-C 0.53 ± 0.18 0.37 ± 0.17 −30.2 0.003* 0.38 ± 0.00 0.35 ± 0.17 −7.9 0.250 0.005* 0.021*
  1. Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
  2. Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-like particles-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol
  3. ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
  4. bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
  5. cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)